Aims To investigate the potential role for a biological boost in anal cancer by assessing whether subvolumes of high 18F-fluorodeoxyglucose (FDG) avidity, identified at outset, are spatially consistent during a course of chemoradiotherapy (CRT).
Materials and methods FDG-positron emission tomography (FDG-PET) scans from 21 patients enrolled into the ART study (NCT02145416) were retrospectively analysed. In total, 29 volumes including both primary t... Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Accepted Manuscript
- Elsevier Publisher's website
- Clinical Oncology Journal website
- Publication date:
- Acceptance date:
- Pubs id:
- Local pid:
- Copyright holder:
- Elsevier Ltd.
- Copyright date:
- © 2018 Published by Elsevier Ltd on behalf of The Royal College of Radiologists. All rights reserved. This is the accepted manuscript version of the article. The final version is available online from Elsevier at: https://doi.org/10.1016/j.clon.2018.11.034
Is there a role for an 18F-fluorodeoxyglucose-derived biological boost in squamous cell anal cancer?
If you are the owner of this record, you can report an update to it here: Report update to this record